This is a decommissioned version of ERA which is running to enable completion of migration processes. All new collections and items and all edits to existing items should go to our new ERA instance at https://ualberta.scholaris.ca - Please contact us at erahelp@ualberta.ca for assistance!
- 327 views
- 585 downloads
Veterinary compounding: In vitro assessment of Methimazole-based foam for feline hyperthyroidism
-
- Author / Creator
- Alshikhey,Areej
-
Veterinary compounding: In vitro assessment of Methimazole-based foam for feline hyperthyroidism Areej Alshikhey, Raimar Löbenberg, Michael Doschak Objective: Hyperthyroidism is one of the most common feline endocrine disorders due to excess production of active thyroid hormone in middle-aged cats. The management involves oral or transdermal antithyroid drug delivery. The use of transdermal medications in cats has become popular in veterinary medicine due to the ease of administration compared to oral medications. We hypothesized that microemulsion-based system could improve the in vitro flux of Methimazole using a Franz cell model.
Method: A concentrations of 2.5% of Methimazole were incorporated into Labrafac-based microemulsion formulations with Labrasol as a surfactant and Plurol Oleique as cosurfactant to be used for transdermal delivery of Methimazole. The in vitro studies were carried out using Franz cell apparatus with a diffusional surface area of 1.79 cm2 and synthetic membranes. A direct comparison of release profiles using Franz diffusion cells between Methimazole-loaded microemulsion and commercial formulations of transdermal Methimazole were performed. Purified water was used as the receptor fluid, and the temperature maintained at 32 ± 0.5°C. The withdrawn samples were appropriately diluted and calculated at different time points 30 min, 1, 2, 4, and 6hrs using HPLC. Result: The obtained result of in vitro study indicated that the foamable microemulsion system might be a candidate carrier for transdermal delivery of Methimazole. Cumulative drug percentage releases through hydrophobic synthetic membranes into the receptor media were found to be 84.64% in Methimazole-loaded microemulsion compared to 47.86%, 33.53%, 33.08% in Lipoderm, Versapro, PLO vehicle, respectively, p< 0.05. Conclusion: Hence the microemulsion system is one of the promising tools for percutaneous delivery of Methimazole. The release profiles obtained from in vitro permeability tests might be used for predicting the in vivo permeability of the formulation. Findings from the current research work evidenced that foam-based microemulsion formulation was superior to cream-based formulations; thus, ME-based foam might be a potential vehicle for enhancing the transdermal penetration of Methimazole. -
- Subjects / Keywords
-
- Graduation date
- Fall 2018
-
- Type of Item
- Thesis
-
- Degree
- Master of Science
-
- License
- Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of these terms. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.